Small molecule stat3 inhibitor for treating triple negative breast cancer
AssigneesUniversity of Maryland, Baltimore, University of Florida Research Foundation, Inc.
InventorsJiayuh LIN, Li PAN, Chenglong LI
Life of this patent
Estimating the term…
Abstract
Methods of using the small molecule STAT3 inhibitor LLL 12B in the treatment of cancer, such as triple-negative breast cancer (TNBC) and pancreatic cancer, either alone or in combination with additional therapeutic agents, such as PARP inhibitors and CDK inhibitors, are provided.
Claims27
1-41. (canceled)
A method of treating cancer in a subject, comprising administering a therapeutically-effective amount of LLL12B to a subject in need thereof, thereby treating cancer in a subject.
A method of treating cancer in a subject, comprising administering a therapeutically-effective amount of LLL12B and one or more additional therapeutic agents to a subject in need thereof, thereby treating cancer in a subject.
A method of inhibiting STAT3 activity in vivo, comprising administering to a subject having cells expressing STAT3 an amount of LLL12B effective to inhibit STAT3 activity, thereby inhibiting STAT3 activity in vivo.
Dependencies are inferred from the claim text.